Human Experiment Begins on Domestic Spray Vaccine

Native Spray Asida Human Experiment Begins
Native Spray Asida Human Experiment Begins

Industry and Technology Minister Mustafa Varank in Nanograf firm Graf Series Production Facility Opening Ceremony, continuing the same company under the umbrella of Turkey's first intranasal (spray vaccine) touched on the domestic vaccine development. Stating that Phase-1 human trials will start in a very short time for the first intranasal vaccine candidate whose preclinical stages have been successfully completed, Varank said, “TITCK's approval is expected. After the rapid completion of all clinical stages, we aim to introduce this new type of vaccine throughout the year. " said.

Minister Varank attended the opening ceremony of Nanography Company Graphene Mass Production Facility in İvedik Organized Industrial Zone (OSB). Giving information about the vaccine studies carried out within the scope of combating Covid-19, Varank said:

The company, which has been successful in the field of nanotechnology, started to work in the field of vaccines during the pandemic. Scientists operating under the umbrella of nanography are developing an innovative type of vaccine to be applied as a nasal spray, unlike conventional vaccines. METU, Hacettepe, Gazi University in Ankara and infrastructure, skills and scientific progress, Turkey's first indigenous intranasal vaccine development work with the contribution of academic experience. Unlike mRNA and inactive vaccine technology, this vaccine was designed as protein-based.

Since the vaccine administered through the nose follows the path in which the virus infects people, it is predicted that this technology will fight the virus more effectively. This type of vaccine has the potential to remodel very quickly in the case of mutation and to strengthen our hand in the possible further course of the outbreak. Phase-1 human trials will begin in a very short time for our first intranasal vaccine candidate, whose preclinical stages have been successfully completed. TITCK's approval is awaited. After the rapid completion of all clinical stages, we aim to introduce this new type of vaccine throughout the year.

Training:

What is CEDES?

EIAES is an important part of the environmental impact assessment process. This system supports sustainable development by analyzing the impacts of projects on the environment. Learn more about EIAES. [more…]